New Delhi, July 07, 2015: Biotechnology firm Transgene BiotekBSE 4.67 % has received patent in the US for its novel molecule to be developed for treatment of liver cancer.
“This granting of a USA patent is a significant step in moving ahead with the development of this novel drug,” Transgene Biotek said in a filing to the BSE.
The company’s novel molecule miRNA 101 for therapy against liver cancer has been allowed for issuance of a USA patent after the prosecution on merits have been closed, it added.
Hepato-cellular cancer (HCC) is the most common primary liver cancer, accounting to roughly 90 per cent of this class of malignancy, with poor prognosis due to its ability to rapidly spread, Transgene Biotek said.
The company’s current product portfolio covers segments such as oncology, auto-immunity, drug delivery and bio-generics.
Shares of Transgene Biotek closed 4.90 per cent up at Rs 2.57 per scrip on the BSE. PTI
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…